Get the Stockscreener App
3.865
0.42%
-0.005
Arbutus Biopharma Corp stock is traded at $3.865, with a volume of 323.52K.
It is down -0.42% in the last 24 hours and up +0.36% over the past month.
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
See More
Previous Close:
$3.87
Open:
$3.86
24h Volume:
323.52K
Relative Volume:
0.32
Market Cap:
$731.53M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-8.4022
EPS:
-0.46
Net Cash Flow:
$-78.92M
1W Performance:
-4.61%
1M Performance:
+0.36%
6M Performance:
+42.20%
1Y Performance:
+100.71%
1-Day Range:
$3.80
$3.89
1-Week Range:
$3.80
$4.03
52-Week Range:
$1.70
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Arbutus Biopharma (ABUS) Set to Announce Earnings on Wednesday - MarketBeat
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
SG Americas Securities LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Target of Unusually High Options Trading (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma Corp (ABUS) Stock: A Year of Declines and Increases - The InvestChronicle
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 5.7%Still a Buy? - MarketBeat
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLDThe Liver Meeting® 2024 - Yahoo Finance
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat
Arbutus Biopharma announces officer retirement terms By Investing.com - Investing.com South Africa
Arbutus Biopharma announces officer retirement terms - Investing.com India
Arbutus Biopharma CSO Michael Sofia Announces Retirement Plans - TipRanks
Examining Arbutus Biopharma Corp (ABUS) stock is warranted - US Post News
Arbutus Biopharma Corp [ABUS] stock for 32,637 USD was sold by MANCHESTER KEITH S - Knox Daily
Balance Sheet Dive: Arbutus Biopharma Corp (ABUS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Top investors say Arbutus Biopharma Corp (ABUS) ticks everything they need - SETE News
XTX Topco Ltd Buys Shares of 17,038 Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Jefferies Upgrades Arbutus Biopharma Corp (ABUS) to a Buy from a Hold - Knox Daily
How to interpret Arbutus Biopharma Corp (ABUS)’s stock chart patterns - US Post News
Taking on analysts’ expectations and winning: Arbutus Biopharma Corp (ABUS) - SETE News
Arbutus Biopharma Corp (ABUS)’s Day in Review: Closing at 3.85, Up by 0.52 - The Dwinnex
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference - Yahoo Finance
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 8.3% in September - MarketBeat
Wall Street SWOT: Arbutus Biopharma stock navigates legal wins and pipeline focus - Investing.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 2.8% - MarketBeat
Rhumbline Advisers Purchases 14,607 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
It would be worthwhile to take a closer look at Arbutus Biopharma Corp (ABUS) - US Post News
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? - Yahoo Finance
The growth track for Arbutus Biopharma Corp (ABUS) has changed recently - SETE News
Analyzing Ratios: Arbutus Biopharma Corp (ABUS)’s Financial Story Unveiled - The Dwinnex
Rubric Capital Management LP Invests $5.20 Million in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
ABUS (Arbutus Biopharma) Altman Z-Score : 0.43 (As of Sep. 20, 2024) - GuruFocus.com
Arbutus Biopharma Co. (NASDAQ:ABUS) Stock Position Lifted by Bank of New York Mellon Corp - Defense World
Arbutus Biopharma Corp (ABUS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Arbutus Biopharma Corp (ABUS)’s stock chart: A technical perspective - US Post News
Arbutus Biopharma Corp’s Banking’s 100-Day Moving Average at 3.47: Will the Stock Break Through? - The InvestChronicle
What is Arbutus Biopharma Corp (ABUS) Stock Return on Shareholders’ Capital? - SETE News
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 8.7% in August - Defense World
Principal Financial Group Inc. Lowers Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Metric Analysis: Arbutus Biopharma Corp (ABUS)’s Key Ratios in the Limelight - The Dwinnex
Arbutus Biopharma Corporation (ABUS): Analysts Are Bullish On This Best Debt-Free Penny Stock Now - Insider Monkey
Arbutus Biopharma Corp’s Banking’s 100-Day Moving Average at 3.43: Will the Stock Break Through? - The InvestChronicle
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 3.5% - MarketBeat
What was Arbutus Biopharma Corp (ABUS)’s performance in the last session? - US Post News
Analytical Lens: Exploring Arbutus Biopharma Corp (ABUS)’s Financial Story Through Ratios - The Dwinnex
Biopharma Layoff Tracker 2024: Connect Biopharma, BioMarin and More Cut Staff - BioSpace
Taking the lead: Arbutus Biopharma Corp (ABUS) - SETE News
Arbutus Biopharma (NASDAQ:ABUS) Sets New 12-Month High at $4.56 - MarketBeat
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year? - Yahoo Finance
Market Momentum Report: Arbutus Biopharma Corp (ABUS)’s Positive Close at 4.51 - The Dwinnex
Arbutus Biopharma (NASDAQ:ABUS) Price Target Increased to $7.00 by Analysts at Jefferies Financial Group - Defense World
Arbutus Biopharma (NASDAQ:ABUS) PT Raised to $7.00 - MarketBeat
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arbutus Biopharma Corp Stock (ABUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MANCHESTER KEITH S | Director |
Aug 14 '24 |
Sale |
3.69 |
8,846 |
32,637 |
46,069 |
| Sims Karen | Chief Medical Officer |
Feb 02 '24 |
Sale |
2.31 |
4,358 |
10,078 |
125,542 |
| HASTINGS DAVID C | Chief Financial Officer |
Feb 02 '24 |
Sale |
2.31 |
9,593 |
22,184 |
181,907 |
| Sofia Michael J. | Chief Scientific Officer |
Feb 02 '24 |
Sale |
2.31 |
9,982 |
23,083 |
1,485,121 |
| McElhaugh Michael J. | Interim President & CEO |
Feb 02 '24 |
Sale |
2.31 |
10,164 |
23,504 |
1,504,793 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):